
New Model Transforms Multiple Myeloma Risk Prediction
A team of researchers has developed a powerful new tool that could transform how doctors treat multiple myeloma, a complex and often unpredictable blood cancer.
A team of researchers has developed a powerful new tool that could transform how doctors treat multiple myeloma, a complex and often unpredictable blood cancer.
ISB Professor Sui Huang challenges the prevailing view of cancer as purely genetic in a new essay published in PLOS Biology. Huang and colleagues argue that many cancers lack identifiable driver mutations, suggesting non-genetic factors and disrupted gene regulatory networks may play crucial roles in cancer development.
ISB researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.
Institute for Systems Biology (ISB) is a collaborative and cross-disciplinary non-profit biomedical research organization based in Seattle. We focus on some of the most pressing issues in human health, including aging, brain health, cancer, COVID-19, as well as many infectious diseases. Our science is translational, and we champion sound scientific research that results in real-world clinical impacts. ISB is an affiliate of Providence, one of the largest not-for-profit health care systems in the United States.